Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6064190 | Journal of Allergy and Clinical Immunology | 2015 | 14 Pages |
Abstract
MK-8237, 12 DU, reduced nasal and ocular symptoms and exceeded World Allergy Organization-established clinical efficacy criteria (â¥20% improvement vs placebo). The onset of action for 12 DU of MK-8237 was week 8. MK-8237, 12 DU, is appropriate for further evaluation to determine the magnitude of effect in an uncontrolled allergen exposure environment.
Keywords
Total ocular symptom scoreSCITSLITVASMIDHDMTOSSEECTNSSsublingual immunotherapy tabletVCCAARTSSAllergic rhinoconjunctivitisAllergen immunotherapysubcutaneous immunotherapySublingual immunotherapyMinimally important differenceAllergic rhinitisOnset of actionadverse eventOcular symptomsTotal Symptom Scoreenvironmental exposure chambervisual analog scaleNasal symptomsTotal nasal symptom scoreDose responseHouse dust mite
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hendrik MD, PhD, Jennifer MD, Harold S. MD, David I. MD, Susan PharmD, Ziliang PhD, Amarjot PhD, Petra MD, René Dipl Ing, Patrick PhD, Friedrich MD,